Human serum albumin, systemic inflammation, and cirrhosis
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · Fundació Clínic per a la Recerca Biomèdica · +5 more institutions
Abstract
Human serum albumin (HSA) is one of the most frequent treatments in patients with decompensated cirrhosis. Prevention of paracentesis-induced circulatory dysfunction, prevention of type-1 HRS associated with bacterial infections, and treatment of type-1 hepatorenal syndrome are the main indications. In these indications treatment with HSA is associated with improvement in survival. Albumin is a stable and very flexible molecule with a heart shape, 585 residues, and three domains of similar size, each one containing two sub-domains. Many of the physiological functions of HSA rely on its ability to bind an extremely wide range of endogenous and exogenous ligands, to increase their solubility in plasma, to…
Citation impact
- FWCI
- 8.72
- Percentile
- 100%
- References
- 162
Authors
3- VAVicente ArroyoCorresponding
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació Clínic per a la Recerca Biomèdica, Universitat de Barcelona, Hospital Clínic de Barcelona
- RGRita García‐Martínez
Fundació Clínic per a la Recerca Biomèdica
- XSXavier Salvatella
Universitat Politècnica de Catalunya, Institute for Research in Biomedicine, Institució Catalana de Recerca i Estudis Avançats
Topics & keywords
- Human serum albumin
- Albumin
- Inflammation
- Cirrhosis
- Systemic inflammation
- Spontaneous bacterial peritonitis
- Serum albumin
- Catabolism
- Good health and well-being